Foley Hoag Represents Morphic Therapeutic in $51.5 Million Series A Financing
June 30, 2016
Foley Hoag LLP recently represented Waltham, MA-based Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin drugs for a wide range of diseases, in its $51.5 million Series A financing.
Morphic Therapeutic was founded to translate the advances from the laboratory of Tim Springer, Ph.D. (Harvard Medical School, Boston Children’s Hospital) into new therapies for immunological, fibrotic, neoplastic and vascular diseases. Morphic Therapeutic is leveraging recent discoveries from Dr. Springer’s lab that may overcome the challenges that limited prior attempts to create small molecule integrin inhibitors.
The round was co-led by biotech investors SR One and Pfizer Venture Investments, who were also joined by new investors Omega Funds and AbbVie, and existing founding investors Polaris Partners, T. A. Springer, Schrödinger, Inc. and ShangPharma Investment Group.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.